M Pharmaceutical Inc. Enters Into Exclusive Negotiations to Acquire Private Pharmaceutical Company with an FDA Approved Women’s Health Product

VANCOUVER, BC / ACCESSWIRE / September 12, 2016 / M Pharmaceutical Inc. (CSE:MQ, OTCQB: MPHMF, FWB:T3F2 ), (the “Company” or “M Pharma”), is announcing that the Company has entered into a 30 day exclusive negotiating period in respect to a possible acquisition of a private pharmaceutical company which holds an FDA approved women’s health product.

As M Pharma moves ahead with its recently acquired patented Chelatexx technology and its existing Trimeo weight loss capsules, the Company is taking steps to broaden its portfolio of drug treatments and biomedical technologies beyond the obesity field.

“With this potential acquisition, we would expand into the women’s health market. Our initial review of the product under investigation leads us to believe that this would be a potential breakthrough product in the women’s health space,” noted M Pharma President & CEO, Mr. Brian Keane.

About M Pharmaceutical Inc.

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to its recent acquisition of C-103, a reformulation of Orlistat from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights.

M Pharma trades on the Canadian Securities Exchange (CSE) under the ticker symbol “MQ” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”

For more information contact:

Investor Relations
Phone: +1 604 428 0511
info@m-pharma.ca
www.m-pharma.ca

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the acquisition of additional biomedical technologies and the commercialization of the rights to the Company’s biomedical and drug technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies

Notice regarding investigational devices: C-103 and Trimeo are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

SOURCE: M Pharmaceutical Inc.

ReleaseID: 445073